Skip to main content
. 2003 Mar;23(5):1647–1655. doi: 10.1128/MCB.23.5.1647-1655.2003

TABLE 2.

Plasmids used in this study

Construct Vectora
LexA-PalA pLexA(1-202)+PL
GAD-PalA pACTII
GST-PalA pGEX-2T
GAD-PacC(341-678) pACTII
GAD-PacC(341-529) pACTII
GAD-PacC(341-529)Y455D pACTII
GAD-PacC(529-678) pACTII
GAD-PacC(529-678)Y662N pACTII
GST-PacC(529-678) pGEX-2T
GST-PacC(169-410) pGEX-2T
His-PacC pD1
His-PacCL340S pD1
His-PacCY455D-Y662N pD1
LexA-SVMYPTLRGL pLexA(1-202)+PL
LexA-SVMAPTLRGL pLexA(1-202)+PL
LexA-SVMYATLRGL pLexA(1-202)+PL
LexA-SVMYPALRGL pLexA(1-202)+PL
LexA-SVMYPTARGL pLexA(1-202)+PL
LexA-SVMNPTLRGL pLexA(1-202)+PL
LexA-Vps32 pLexA(1-202)+PL
GAD-AIP1/Alix pACTII
a

Vectors are pLexA(1-202) + PL (37), pACTII (Clontech), pGEX-2T (Pharmacia), and pD1, a pET19b-derived plasmid that allows the expression of N-terminally His-tagged proteins under the control of a T7 polymerase-dependent promoter (10).